Treatment of sexual dysfunction in certain patient groups

Abstract

Methods for treating specific patient groups for sexual dysfunction are provided. The methods of the present invention comprise the utilization of pharmaceutical compositions in patients who are free of cardiac disease and/or who have not been given organic nitrates.

1 . A method, comprising: 
 a) providing: 
 i) a subject diagnosed with erectile dysfunction who is free of cardiac disease; and  
 ii) a therapeutic formulation comprising a quinoline; and  
   b) introducing said formulation to said subject such that an erection is produced.    
     
     
         2 . The method of  claim 1 , wherein said quinoline is a halogenated quinoline.  
     
     
         3 . The method of  claim 2 , wherein said halogenated quinoline is flosequinan.  
     
     
         4 . The method of  claim 3 , wherein said flosequinan is introduced into said subject by oral administration.  
     
     
         5 . The method of  claim 4 , wherein said subject is an adult human and said oral administration comprises up to approximately 100 milligrams of flosequinan.  
     
     
         6 . The method of  claim 3 , wherein said flosequinan is introduced into said subject cutaneously.  
     
     
         7 . The method of  claim 3 , wherein said flosequinan is introduced into said subject transurethrally.  
     
     
         8 . The method of  claim 3 , wherein said flosequinan is introduced into said subject intracavernosally.  
     
     
         9 . The method of  claim 1 , wherein said subject is a male.  
     
     
         10 . The method of  claim 1 , wherein said subject is a female.  
     
     
         11 . A method, comprising: 
 a) providing: 
 i) a subject diagnosed with erectile dysfunction, wherein said subject is not being treated with a drug that causes hypotensive effects; and  
 ii) a therapeutic formulation comprising a quinoline; and  
   b) introducing said formulation to said subject such that an erection is produced.    
     
     
         12 . The method of  claim 11 , wherein said quinoline is a halogenated quinoline.  
     
     
         13 . The method of  claim 12 , wherein said halogenated quinoline is flosequinan.  
     
     
         14 . The method of  claim 13 , wherein said flosequinan is introduced into said subject by oral administration.  
     
     
         15 . The method of  claim 13 , wherein said flosequinan is introduced into said subject cutaneously.  
     
     
         16 . The method of  claim 13 , wherein said flosequinan is introduced into said subject transurethrally.  
     
     
         17 . The method of  claim 13 , wherein said flosequinan is introduced into said subject intracavernosally.  
     
     
         18 . The method of  claim 11 , wherein said subject is a male.  
     
     
         19 . The method of  claim 11 , wherein said subject is a female.  
     
     
         20 . The method of  claim 11 , wherein said subject has not been treated in the past with a drug that causes hypotensive effects.  
     
     
         21 . A method, comprising: 
 a) providing: 
 i) a subject diagnosed with erectile dysfunction, wherein said subject is not being treated with a nitrite or nitrate; and  
 ii) a therapeutic formulation comprising a quinoline; and  
   b) introducing said formulation to said subject such that an erection is produced.    
     
     
         22 . The method of  claim 21 , wherein said quinoline is a halogenated quinoline.  
     
     
         23 . The method of  claim 22 , wherein said halogenated quinoline is flosequinan.  
     
     
         24 . The method of  claim 23 , wherein said flosequinan is introduced into said subject by oral administration.  
     
     
         25 . The method of  claim 23 , wherein said flosequinan is introduced into said subject cutaneously.  
     
     
         26 . The method of  claim 23 , wherein said flosequinan is introduced into said subject transurethrally.  
     
     
         27 . The method of  claim 23 , wherein said flosequinan is introduced into said subject intracavernosally.  
     
     
         28 . The method of  claim 21 , wherein said subject is a male.  
     
     
         29 . The method of  claim 21 , wherein said subject is a female.  
     
     
         30 . The method of  claim 21 , wherein said nitrate is selected from the group consisting of glyceryl trinitrate, isosorbide dinitrate, isosorbide-5-mononitrate and erythrityl tetranitrate.